|
Forecast
Period
|
2026-2030
|
|
Market
Size (2024)
|
USD
192.95 Billion
|
|
Market
Size (2030)
|
USD
291.04 Billion
|
|
CAGR
(2025-2030)
|
7.05%
|
|
Fastest
Growing Segment
|
Dry
|
|
Largest
Market
|
North
America
|
Market Overview
Global
Small Volume Parenteral Market was valued at USD 192.95 Billion in 2024 and is
anticipated to project impressive growth in the forecast period with a CAGR of 7.05%
through 2030. In the realm of business, there has been a consistent increase in
the need for small-volume parenteral solutions (SVPs) owing to the rising
incidence of chronic illnesses and the essential use of intravenous medications
in healthcare institutions. The expanding elderly population, especially in
developed countries, has led to a greater demand for medical treatments. SVPs
are preferred for their convenience in administration and precise dosage, which
is fueling demand in the market. Furthermore, advancements in pharmaceutical
production methods and packaging technologies are enhancing the safety,
quality, and shelf life of SVPs, rendering them a more dependable choice for
healthcare providers and patients.
Key Market Drivers
Increasing Prevalence of
Chronic Diseases
Chronic
diseases are on the rise worldwide, posing a significant challenge to
healthcare systems and providers. In 2021, more than one-third of adults across 24 OECD countries reported living with a longstanding illness or health issue. There is a significant disparity between income levels in relation to health problems. On average, 43% of individuals in the lowest income bracket reported having a long-lasting health problem, compared to only 27% of those in the highest income bracket. This gap is particularly pronounced in countries such as Lithuania, Belgium, Estonia, and Ireland, where individuals in the lowest income group are at least twice as likely to experience health issues compared to their higher-income counterparts. Conditions such as diabetes, cardiovascular
diseases, cancer, and respiratory disorders are becoming increasingly
prevalent, leading to higher demands for medical treatments and therapies. As
the burden of chronic diseases grows, so does the importance of effective
treatment methods, including the use of Small Volume Parenteral (SVP)
solutions. Cardiovascular diseases (CVDs) are the leading cause of death globally, accounting for an estimated 17.9 million deaths each year. CVDs encompass a range of conditions affecting the heart and blood vessels, including coronary heart disease, cerebrovascular disease, rheumatic heart disease, and other related disorders. These diseases continue to pose a significant public health challenge worldwide.
As
chronic diseases become more common, the demand for efficient, safe, and
reliable methods of treatment has grown. Many chronic conditions require
ongoing medication or therapy to manage symptoms and prevent complications.
SVPs are well-suited to this purpose because they allow for the precise
delivery of medication intravenously, ensuring that patients receive the
correct dosage consistently. This accuracy in dosing is essential in managing
chronic diseases, as even slight variations can have a significant impact on
patient health.
Chronic
disease management often involves complex medication regimens, which can be
burdensome for both patients and healthcare providers. SVPs provide a
convenient solution, simplifying the administration of medications. They reduce
the need for multiple injections or frequent oral doses, improving patient
compliance and overall treatment efficiency.
The
rising prevalence of chronic diseases places a substantial economic burden on
healthcare systems. Hospitalizations for chronic disease management can be
costly, and patients often prefer to receive treatment in the comfort of their
homes. SVPs are a valuable tool in facilitating home-based care, reducing the
need for prolonged hospital stays. This not only improves patient quality of
life but also lowers healthcare costs, making them an attractive option for
healthcare providers and payers.
The
scope of SVPs is not limited to a single disease or condition. They are used in
a wide range of therapies, from cancer treatments to pain management and more.
As the prevalence of different chronic diseases increases, the applicability of
SVPs broadens, allowing them to address a diverse set of healthcare needs. This
adaptability is contributing to the market's growth as healthcare providers
explore new ways to utilize SVPs in chronic disease management.
Advancements in
pharmaceutical manufacturing and healthcare technologies have enhanced the
safety and quality of SVPs. Improved packaging, sterilization methods, and
quality control measures have made SVPs more reliable and safer for chronic
disease management, further contributing to their increasing adoption.
Aging Population
The
world is experiencing a significant demographic shift as the global population
ages at an unprecedented rate. This aging population presents a unique set of
challenges and opportunities for healthcare providers and the medical industry. By 2030, 1 in 6 people globally will be aged 60 years or older. The population in this age group is projected to grow from 1 billion in 2020 to 1.4 billion by that year. By 2050, the global population of individuals aged 60 and above is expected to double, reaching 2.1 billion. Additionally, the number of individuals aged 80 years or older is forecasted to triple between 2020 and 2050, reaching a total of 426 million. One notable consequence of this demographic transformation is the increasing
demand for medical interventions and treatments, particularly for chronic
conditions. Small Volume Parenteral (SVP) solutions, which facilitate the
precise and controlled administration of intravenous medications, are
well-positioned to benefit from this trend.
One
of the key drivers behind the growing demand for SVP solutions is the higher
incidence of chronic diseases among the elderly population. Conditions such as
diabetes, hypertension, cardiovascular diseases, and arthritis are more
prevalent in older adults. Older adults are particularly affected by chronic conditions, with nearly 95% of them having at least one chronic illness, and approximately 80% managing two or more. In the U.S., the leading causes of death among older adults include heart disease, cancer, COVID-19, stroke, chronic lower respiratory diseases, Alzheimer’s disease, and diabetes. These health challenges disproportionately impact the aging population, contributing to higher mortality rates and a growing need for healthcare interventions. Managing these chronic conditions often requires
consistent and precise administration of medications, a need that SVPs are
designed to fulfill. The aging population's vulnerability to these ailments
fuels the demand for SVPs as a reliable and efficient means of treatment.
Polypharmacy,
the simultaneous use of multiple medications to manage multiple health issues,
becomes more common as individuals age. Elderly patients may require several
medications to address a variety of conditions, from heart disease to
osteoporosis. SVPs offer a convenient and accurate way to administer multiple
drugs safely, minimizing the risk of medication errors and ensuring optimal
therapeutic outcomes. This need for polypharmacy further boosts the adoption of
SVP solutions.
Elderly
patients often face challenges when it comes to self-administering medications.
Declining motor skills and cognitive impairments can make it difficult to
manage oral medications. SVPs simplify the process by providing healthcare
professionals with a reliable method to deliver medications. This convenience
improves patient compliance and enhances the overall quality of healthcare for
the aging population.
The
aging population's increasing demand for medical services puts pressure on
healthcare facilities and budgets. Hospital stays can be both costly and
disruptive to elderly patients. SVPs allow for many treatments to be
administered in an outpatient setting or even at home, reducing the need for
prolonged hospitalization. This not only eases the burden on healthcare systems
but also enhances the comfort and quality of life for elderly patients.
Advancements
in pharmaceutical manufacturing, packaging, and healthcare technologies have
enhanced the safety and reliability of SVP solutions. These improvements
include better sterilization techniques, packaging materials, and quality
control measures, which are particularly important for elderly patients who may
have weakened immune systems. Such advancements further support the adoption of
SVPs for the aging population.
Advancements in Pharmaceutical
Manufacturing
The
global healthcare landscape is continuously evolving, driven by technological
breakthroughs and innovations that revolutionize patient care. Advancements in
pharmaceutical manufacturing play a pivotal role in shaping the future of
healthcare delivery. One area where these advancements are particularly
significant is in the Small Volume Parenteral (SVP) market. SVPs, intravenous
solutions designed for precise drug administration, are benefiting greatly from
cutting-edge pharmaceutical manufacturing technologies. In 2021, North America represented 49.1% of global pharmaceutical sales, while Europe accounted for 23.4%. Between 2016 and 2021, 64.4% of sales from newly launched medicines were in the U.S. market, compared to 16.8% in the European market. This highlights the dominance of North America, particularly the U.S., in driving pharmaceutical sales and the uptake of new medicines.
One
of the most significant contributions of advancements in pharmaceutical
manufacturing is the improvement in product safety and quality. Stringent
quality control measures and manufacturing processes have reduced the risk of
contamination, ensuring that SVPs meet the highest safety standards. This
increased product safety instills confidence in healthcare providers and
patients, fostering a higher demand for SVP solutions.
Pharmaceutical
manufacturing innovations have led to the development of more robust packaging
and storage methods. This results in extended shelf life for SVP products. As
these products remain stable and effective for longer durations, healthcare
providers can maintain larger inventories, and patients can access these
medications over extended periods. The reliability of SVPs due to their longer
shelf life further fuels market growth.
Advancements
in pharmaceutical manufacturing have led to more precise control over the
composition of SVPs. This precision is crucial for ensuring the accurate dosage
of medications. In a healthcare landscape where precision is of paramount
importance, SVPs have become the go-to solution for administering critical
medications. Accurate dosing minimizes the risk of complications and improves
patient outcomes, making SVPs a preferred choice for healthcare providers.
Modern
pharmaceutical manufacturing processes offer greater flexibility in tailoring
SVPs to meet specific patient needs. The ability to customize medications in
terms of concentration and composition enables healthcare professionals to
provide more individualized treatment regimens. This customization capability
not only enhances patient care but also opens up new opportunities for
pharmaceutical companies in the SVP market.
In
recent years, sustainability has become a focal point in pharmaceutical
manufacturing. Manufacturers are increasingly adopting environmentally friendly
practices, from reducing waste to utilizing energy-efficient processes. Such
eco-conscious efforts are not only beneficial for the environment but also
resonate with consumers who are becoming more environmentally aware.
Sustainable practices in pharmaceutical manufacturing can improve a company's
reputation and drive consumer preference for their SVP products.
Pharmaceutical
manufacturers are continually working to meet evolving regulatory standards.
Staying compliant with international regulations ensures the safety and quality
of SVPs. As companies invest in research and development to meet these
standards, the resultant products gain a competitive edge in the global market.
Rising Demand for Home
Healthcare
The
landscape of healthcare is experiencing a transformative shift, with more
patients and healthcare providers recognizing the advantages of home-based
care. This paradigm shift is giving rise to a significant increase in the
demand for home healthcare services. One crucial player in this evolution is
the Small Volume Parenteral (SVP) market. SVP solutions, which enable the
precise and safe administration of intravenous medications, are perfectly
suited for home healthcare applications.
One
of the primary drivers behind the surge in home healthcare is the preference
for receiving care in the comfort of one's home. Patients often find home-based
care more convenient and less disruptive to their daily lives. This preference
extends to the administration of medications, where SVPs play a pivotal role by
providing an efficient and reliable means of intravenous drug delivery.
Home
healthcare allows patients to receive the care they need without the need for
extended hospital stays or frequent clinic visits. The use of SVPs simplifies
the process of administering medications, making it easier for both patients
and their caregivers to manage treatment regimens. This convenience not only
improves the patient's quality of life but also enhances overall treatment
efficiency.
Hospitalizations
are expensive, and home healthcare can be a cost-effective alternative. By
shifting the administration of certain medications to home-based care,
healthcare systems can reduce the financial burden on patients and insurance
providers. SVPs allow for precise and safe drug administration outside of a
healthcare facility, thus contributing to cost savings.
Home
healthcare is particularly beneficial for patients with chronic diseases, a
group that is steadily expanding due to an aging population and increasing
rates of chronic conditions. SVPs are essential in the management of these
diseases, offering patients the ability to receive their medications
consistently and accurately without the need for frequent hospital visits.
The
applications of SVPs are not limited to a single medical condition, which makes
them a versatile solution for home healthcare. They are used in various
therapies, including oncology, pain management, and palliative care. The
versatility of SVPs allows them to address the diverse healthcare needs of
patients in a home setting.
Download Free Sample Report
Key Market Challenges
Sterility and Contamination
Concerns
Sterility
is paramount in the manufacturing and distribution of SVP products.
Contaminated products can have severe consequences for patients, including
life-threatening infections. Maintaining sterility during the entire production
and distribution process remains a significant challenge. Stringent aseptic
manufacturing processes, advanced sterilization techniques, and proper
packaging are vital in mitigating contamination risks.
Economic Pressures
The
cost of producing and distributing SVP solutions, especially those designed for
home healthcare, can be relatively high. Economic pressures within the
healthcare industry and the need for cost-effective solutions are challenges
that manufacturers must confront. Balancing product affordability with quality
and safety is an ongoing concern for the SVP market.
Competition and Market
Saturation
The
SVP market has witnessed significant growth in recent years, attracting
numerous manufacturers and suppliers. As the market becomes increasingly
crowded, competition has intensified. Manufacturers must find ways to
differentiate their products and expand into niche markets to maintain growth.
Key Market Trends
Personalized Medication
Compounding
As
healthcare becomes increasingly patient-centric, the demand for personalized
medication compounding is on the rise. Patients with unique healthcare needs
require customized SVP solutions tailored to their specific conditions and
preferences. This trend is driving pharmaceutical manufacturers to develop
flexible compounding techniques and customized packaging to cater to these
individualized requirements.
Sustainability and
Environmental Responsibility
Sustainability
is not just a buzzword but a global imperative, and the pharmaceutical industry
is no exception. Manufacturers are under increasing pressure to adopt
environmentally responsible practices, from reducing plastic waste in packaging
to minimizing energy consumption in production. This trend is reshaping the SVP
market, as companies explore eco-friendly materials and more sustainable
manufacturing processes.
Specialized Formulations and
Therapies
The
SVP market is diversifying to address an array of medical conditions and
therapies. Specialized formulations, such as those for oncology, pain
management, and palliative care, are gaining prominence. As the demand for
niche and targeted therapies grows, pharmaceutical manufacturers are developing
SVP solutions to meet these specific medical needs.
Segmental Insights
Form Insights
In
2024, the dry formulation category held the largest market share. Dry
Single-Vial Preparations (SVPs) typically have a longer shelf life compared to
their liquid counterparts. Furthermore, they provide dosing flexibility, as
healthcare providers can mix the medication with a specified amount of liquid
to achieve the desired concentration. Additionally, the lyophilization process
reduces the risk of microbial contamination, making dry SVPs advantageous for
medications that degrade in liquid form.
Type Insights
Based
on Type, the single-dose containers segment dominated the market in 2024.
Single-dose containers, such as vials, ampules, and prefilled syringes, are
designed for the administration of a single injection or infusion to a single
patient and are not subject to antimicrobial effectiveness testing
requirements. This category's growth is attributed to factors like the reduced
risk of contamination, maintenance of sterility, precise dosing, and the
convenience and efficiency it offers.
Download Free Sample Report
Regional Insights
In
2024, North America secured the largest share of revenue. This was primarily
driven by several key factors, including substantial research investments from both
private entities and government agencies within the healthcare sector, the
presence of advanced medical technology, and collaborative efforts among the
medical device industry, regulatory authorities, universities, and other
stakeholders. Furthermore, the region's high incidence of chronic diseases such
as cancer and malnutrition, coupled with the availability of advanced
healthcare facilities and favorable reimbursement policies and regulations,
resulted in a high rate of hospital admissions, thereby bolstering product
demand.
Recent Developments
- In September 2024, Syntegon, a prominent provider of pharmaceutical packaging solutions and process technology, has introduced its small volume parenteral (SVP) pharmaceutical processing system. This system leverages fully standardized platforms, incorporating off-the-shelf functional modules to enhance efficiency and scalability in pharmaceutical manufacturing.
- In October 2023, At the 2023 PDA Universe of Pre-Filled Syringes and Injection Devices Conference in Gothenburg, ZACROS, a leading Japanese pharmaceutical packaging developer, unveiled its innovative MediTect flexible packaging technology designed specifically for sensitive parenteral drugs. The company is showcasing the new solution at Booth 138 during the event, highlighting its commitment to advancing packaging solutions for the pharmaceutical industry.
- In
July 2022, Akums Drugs & Pharmaceuticals Ltd., a well-established
pharmaceutical contract manufacturing firm based in India, successfully secured
European Union Good Manufacturing Practice (EU GMP) certification for two of
its manufacturing facilities located in Haridwar.
Key Market Players
- BML
Parenteral Drugs
- Rusoma Laboratories Pvt Ltd
- B Braun Melsungen AG
- Fresenius Kabi AG
- Baxter International Inc.
- Sichuan Kelun Pharmaceutical Co Ltd
|
By
Form
|
By
Type
|
By
Packaging
|
By
Indication
|
By
Region
|
|
|
|
- Ampoules
- Vials
- Pre-filled
Syringes
- Cartridges
- Bottles
- Others
|
- Pain
Management
- Cancer
Care
- Malnourishment
- Gastrointestinal
Disorder/Diarrhea
- Diabetes
- Others
|
- North
America
- Europe
- Asia-Pacific
- South
America
- Middle
East & Africa
|
Report Scope:
In this report, the Global Small Volume Parenteral
Market has been segmented into the following categories, in addition to the
industry trends which have also been detailed below:
- Small Volume Parenteral Market, By Form:
o Liquid
o Dry
- Small Volume Parenteral Market, By Type:
o Single-dose
o Multiple-dose
- Small Volume Parenteral Market, By Packaging:
o Ampoules
o Vials
o Pre-filled Syringes
o Cartridges
o Bottles
o Others
- Small Volume Parenteral Market, By Indication:
o Pain Management
o Cancer Care
o Malnourishment
o Gastrointestinal
Disorder/Diarrhea
o Diabetes
o Others
- Small Volume Parenteral Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ Germany
§ United Kingdom
§ France
§ Italy
§ Spain
o Asia-Pacific
§ China
§ Japan
§ India
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Small
Volume Parenteral Market.
Available Customizations:
Global Small Volume Parenteral market report
with the given market data, Tech Sci Research offers customizations according
to a company's specific needs. The following customization options are
available for the report:
Company Information
- Detailed analysis and profiling of additional
market players (up to five).
Global Small Volume Parenteral Market is an
upcoming report to be released soon. If you wish an early delivery of this
report or want to confirm the date of release, please contact us at sales@techsciresearch.com